Rituximab/Paclitaxel | Interleukin Related interleukin-related.com

Product Name :
Rituximab/Paclitaxel

Search keywords :
Nab-Paclitaxel

drugId :
null

Target Vo:
B-lymphocyte antigen CD20

Target Vo Short Name :
CD20

Moa_Name:
Tubulin polymerisation inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Mayo Clinic

Active Company_Name :
Mayo Clinic

Active Indication_Name:
Lymphoma, Non-Hodgkin

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Phase 1 Clinical

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Ubiquitin Antibody (YA022)
Phospho-CDK1/2/3 (Thr14) Antibody
PI3 Kinase p85 beta Antibody (YA688): PI3 Kinase p85 beta Antibody (YA688) is a non-conjugated and Mouse origined monoclonal antibody about 82 kDa, targeting to PI3 Kinase p85 beta (8D9). It can be used for WB assays with tag free, in the background of Human, Mouse, Rat.

Author: Interleukin Related

Related Posts